Zymeworks is a global biotechnology company developing novel, multifunctional therapeutics to address difficult-to-treat cancers and other serious diseases. Our complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. Zymeworks is advancing a deep pipeline of antibody-drug conjugates and multispecific antibodies product candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene and Jazz Pharmaceuticals, granting each with exclusive rights to develop and commercialize zanidatamab across the globe. Zymeworks' therapeutic platforms have been leveraged and validated in product development through strategic partnerships with global biopharmaceutical companies.
Ticker:
ZYME
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
BC, Canada
Company HQ Country:
Canada
Year Founded:
2003
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
Zanidatamab
HER2 x HER2 Bispecific Antibody
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
